Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2025, Omnicell, Inc. (the “Company”) announced that Nchacha Etta will step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named.…
Filed Mar 12, 2025Accepted Mar 12, 2025, 8:40 AM EDTCIK 926326Accession 0001104659-25-022797
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 12, 2025, Omnicell, Inc. (the
“Company”) announced that Nchacha Etta will step down from his role as Executive Vice President, Chief Financial Officer of
the Company, effective September 15, 2025 or until a successor is named. Pending his departure, Mr. Etta will continue to serve
as Executive Vice President, Chief Financial Officer while the Company searches for a new Chief Financial Officer and will assist with
the transition of his role and responsibilities.
In connection with Mr. Etta’s departure,
it is expected that the Company and Mr. Etta will enter into a transition agreement, the material terms of which have not been finalized
as of the date of this Current Report on Form 8-K.
The departure of Mr. Etta is not due to any
disagreement with the Company on any matter relating to the Company’s operations, policies or practices (financial reporting, accounting
or otherwise).
The Company would like to thank Mr. Etta for
his contributions to the Company throughout his employment, and for playing an important role in the Company’s growth.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On March 12, 2025, the Company issued a press
release reiterating its first quarter and full year 2025 guidance. A copy of which is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 7.01 of this
Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference into any Company filing under the Securities Act or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Exhibit Description
Number
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press release entitled “Omnicell Announces Chief Financial Officer Transition” dated March 12, 2025
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
Filed exhibits (1)
EX-99.1 (by filename) tm258643d1_ex99-1.htm
EX-99.1
2
tm258643d1_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Contact:
Kathleen Nemeth Omnicell, Inc.
Senior Vice President, Investor 4220 North Freeway
Relations
650-435-3318 Fort Worth, TX 76137
Kathleen. Nemeth@Omnicell.com
Omnicell Announces
Chief Financial Officer Transition
Company Reiterates
First Quarter and Full Year 2025 Guidance
FORT WORTH, Texas - March 12,
2025 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,”
or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta
will be stepping down from his role as Executive Vice President and Chief Financial Officer, effective September 15, 2025 or until
a successor is named. Mr. Etta will continue to serve as Executive Vice President and Chief Financial Officer while Omnicell searches
for a new Chief Financial Officer and will work to ensure a smooth transition of his role and responsibilities. The Company has commenced
a national search for his successor.
“Since joining Omnicell in mid-2023,
Nchacha’s insights and contributions have been invaluable as we worked to int…